Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders.

Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases.

Strasbourg, France, December 4, 2018 – Domain Therapeutics announces a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area. The collaboration combines the expertise of Domain Therapeutics, a French and Canadian biopharmaceutical company, in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim’s expertise in the discovery and clinical development of therapeutics on multiple indications.

Download PDF